Search clinical trials for: AZD0914

Total 76 results

Entasis Therapeutics

Completed

AZD0914 Phase 1 ADME Study in Healthy Volunteers

Healthy

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers

Gonorrhoea

United States
Samsung Medical Center

Withdrawn

Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy (TSC1/2_SC)

Solid Tumor

Korea, Republic of
Massachusetts General Hospital
United States Department of Defense; AstraZeneca

Completed

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Meningioma | Neurofibromatosis 2

United States
AstraZeneca

Completed

Bioavailability of AZD0284 and IV Microtracer Study

Plaque Psoriasis Vulgaris

United Kingdom
AstraZeneca

Recruiting

Study of AZD0754 in Participants With Metastatic Prostate Cancer (APOLLO)

Metastatic Prostate Cancer

United States, Australia
AstraZeneca

Not yet recruiting

LTFU for All Cell and Gene Therapy Studies (LOCUS)

Hepatocellular Carcinoma | Prostate Cancer

United States
Massachusetts General Hospital
National Cancer Institute (NCI); AstraZeneca

Active, not recruiting

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Meningioma

United States
Samsung Medical Center
AstraZeneca

Terminated

Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification ([SUKSES-D])

Small Cell Lung Cancer

Korea, Republic of
Samsung Medical Center

Completed

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
AstraZeneca

Terminated

Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients

Type 2 Diabetes

Sweden
AstraZeneca

Terminated

A Single and Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Japanese Subjects (JSMAD)

Healthy

United Kingdom
Samsung Medical Center

Withdrawn

Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy (RICTOR_SC)

Solid Tumor

Korea, Republic of
AstraZeneca

Terminated

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis (DERMIS)

Plaque Psoriasis Vulgaris

Denmark
AstraZeneca
SCRI Development Innovations, LLC

Completed

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Papillary Renal Cell Cancer

United States, Canada, United Kingdom, Spain
AstraZeneca

Completed

An Open Label Prostate Cancer Study in Japanese Patients

Prostate Cancer

Japan
AstraZeneca

Withdrawn

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (INHIBITOR)

Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
AstraZeneca

Completed

Open Label Prostate Cancer Study

Prostate Cancer

United Kingdom, Netherlands, United States
AstraZeneca

Terminated

A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

Healthy | COPD

Sweden
Royal Marsden NHS Foundation Trust
AstraZeneca; Institute of Cancer Research, United Kingdom

Completed

A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel. (TAX-TORC)

Advanced Cancer

United Kingdom
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants

Rheumatoid Arthritis

United Kingdom, Canada
National Cancer Institute (NCI)

Terminated

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage... and other conditions

United States
Canadian Cancer Trials Group
AstraZeneca

Completed

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Glioblastoma Multiforme

Canada
AstraZeneca
Parexel

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects

Plaque Psoriasis Vulgaris

United Kingdom
AstraZeneca

Active, not recruiting

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca
Quotient Sciences

Completed

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

Cancer

United Kingdom
AstraZeneca

Completed

AZD9164 Single Ascending Dose Study in Healthy Male Subjects

Healthy

Sweden
National Institute of Allergy and Infectious Diseases...

Completed

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

Gonorrhoea

United States
Samsung Medical Center

Terminated

Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy

Cancer of Stomach

Korea, Republic of
Samsung Medical Center

Terminated

Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy (AZD2014)

Stomach Neoplasms

Korea, Republic of
Hutchison Medipharma Limited

Completed

A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers

Bioequivalence

China
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca

Completed

Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer (CaNCaP02)

Prostate Cancer

United Kingdom
AstraZeneca

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

Advanced Solid Malignancies

United Kingdom
Antengene Therapeutics Limited
Bristol-Myers Squibb

Recruiting

Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies (ERASER)

Solid Tumor | Hematological Malignancy

Australia
Queen Mary University of London
AstraZeneca; Cancer Research UK

Unknown

A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers (TORCMEK)

Squamous Cell Lung Cancer | Triple-Negative Breast Cancer | Non-squamous Cell Lung Cancer With KRAS Mutations | Non-squamous Cell Lung Cancer With Wild-type KRAS

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

Gonococcal Infection | Electrocardiogram Repolarisation Abnormality

United States
Jeeyun Lee

Recruiting

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Stomach Cancer, Adenocarcinoma

Korea, Republic of
FibroGen
AstraZeneca

Completed

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Anemia | Myelodysplastic Syndrome

China
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
Cancer Research UK

Terminated

A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours (AZD0424)

Advanced Solid Tumours

United Kingdom
Queen Mary University of London
AstraZeneca; Vall d'Hebron Institute of Oncology

Active, not recruiting

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma (CALYPSO)

Renal Clear Cell Carcinoma | Renal Papillary Cell Carcinoma

United Kingdom
Acerta Pharma BV

Terminated

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

DLBCL | Richter Syndrome

United Kingdom, United States
AstraZeneca
Quintiles, Inc.

Completed

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase (14C)

Solid Malignancies

United Kingdom
Queen Mary University of London
AstraZeneca; Cancer Research UK

Terminated

A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer (ZEBRA)

Metastatic Clear Cell Renal Carcinoma

United Kingdom
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
Samsung Medical Center

Completed

Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

CKD Anemia

United States, Australia, Thailand, Korea, Republic of, Malaysia, Mexico, Taiwan, New Zealand, Argentina, Chile, Colombia, Hong Kong, Peru, Philippines, Puerto Rico, Singapore
Samsung Medical Center

Completed

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
Hutchison Medipharma Limited
AstraZeneca

Completed

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Non-Small Cell Lung Cancer

China

Search clinical trials for: AZD0914

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations